Roy Winston
Insider
First SEC filing: Sept. 7, 2018 · Latest: Sept. 7, 2018
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 2, 2023 | PCRX | S | 509 | $34.88 | $17,754 | 52,440 Direct | -0.96% | Disposed | -29.0% (price as of 2026-10-06) |
| June 14, 2023 | PCRX | A | 27,500 | · | · | 27,500 Direct | · | Acquired | (price as of 2026-10-06) |
| June 14, 2023 | PCRX | A | 10,950 | · | · | 52,306 Direct | +26.48% | Acquired | (price as of 2026-10-06) |
| June 7, 2023 | PCRX | S | 1,857 | $37.86 | $70,306 | 41,356 Direct | -4.30% | Disposed | -34.6% (price as of 2026-10-06) |
| June 6, 2023 | PCRX | S | 1,779 | $38.99 | $69,363 | 43,213 Direct | -3.95% | Disposed | -36.5% (price as of 2026-10-06) |
| Aug. 3, 2022 | PCRX | S | 476 | $55.70 | $26,513 | 44,992 Direct | -1.05% | Disposed | -55.5% (price as of 2026-10-06) |
| June 8, 2022 | PCRX | A | 24,800 | · | · | 24,800 Direct | · | Acquired | (price as of 2026-10-06) |
| June 8, 2022 | PCRX | A | 9,900 | · | · | 45,060 Direct | +28.16% | Acquired | (price as of 2026-10-06) |
| June 6, 2022 | PCRX | M | 6,250 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 123 | $63.69 | $7,834 | 35,160 Direct | -0.35% | Disposed | -61.1% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 1,891 | $62.48 | $118,150 | 35,283 Direct | -5.09% | Disposed | -60.4% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 3,650 | $61.59 | $224,804 | 37,174 Direct | -8.94% | Disposed | -59.8% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 3,533 | $60.55 | $213,923 | 40,824 Direct | -7.96% | Disposed | -59.1% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 115 | $63.40 | $7,291 | 44,357 Direct | -0.26% | Disposed | -60.9% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 1,300 | $62.43 | $81,159 | 44,472 Direct | -2.84% | Disposed | -60.3% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 2,300 | $61.59 | $141,657 | 45,772 Direct | -4.78% | Disposed | -59.8% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 2,535 | $60.55 | $153,494 | 48,072 Direct | -5.01% | Disposed | -59.1% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | M 10b5-1 | 6,250 | $34.38 | $214,875 | 50,607 Direct | +14.09% | Acquired | -28.0% (price as of 2026-10-06) |
| June 6, 2022 | PCRX | S 10b5-1 | 2,099 | $61.37 | $128,816 | 44,357 Direct | -4.52% | Disposed | -59.7% (price as of 2026-10-06) |
| Nov. 4, 2021 | PCRX | M | 10,000 | · | · | 15,000 Direct | -40.00% | Disposed | (price as of 2026-10-06) |
| Nov. 4, 2021 | PCRX | M | 10,000 | $48.15 | $481,500 | 46,456 Direct | +27.43% | Acquired | -48.6% (price as of 2026-10-06) |
| Aug. 3, 2021 | PCRX | A | 10,000 | · | · | 10,000 Direct | · | Acquired | (price as of 2026-10-06) |
| Aug. 3, 2021 | PCRX | A | 5,000 | · | · | 36,456 Direct | +15.90% | Acquired | (price as of 2026-10-06) |
| June 9, 2021 | PCRX | A | 7,000 | · | · | 31,035 Direct | +29.12% | Acquired | (price as of 2026-10-06) |
| June 9, 2021 | PCRX | A | 17,500 | · | · | 17,500 Direct | · | Acquired | (price as of 2026-10-06) |
| June 4, 2021 | PCRX | S | 2,276 | $61.04 | $138,927 | 24,035 Direct | -8.65% | Disposed | -59.4% (price as of 2026-10-06) |
| March 31, 2021 | PCRX | M | 13,750 | · | · | 6,250 Direct | -68.75% | Disposed | (price as of 2026-10-06) |
| March 31, 2021 | PCRX | S 10b5-1 | 1,200 | $72.12 | $86,544 | 26,311 Direct | -4.36% | Disposed | -65.7% (price as of 2026-10-06) |
| March 31, 2021 | PCRX | S 10b5-1 | 4,661 | $71.09 | $331,350 | 27,511 Direct | -14.49% | Disposed | -65.2% (price as of 2026-10-06) |
| March 31, 2021 | PCRX | S 10b5-1 | 16,363 | $70.36 | $1,151,301 | 32,172 Direct | -33.71% | Disposed | -64.8% (price as of 2026-10-06) |
| March 31, 2021 | PCRX | M 10b5-1 | 13,750 | $34.38 | $472,725 | 48,535 Direct | +39.53% | Acquired | -28.0% (price as of 2026-10-06) |
| Nov. 13, 2020 | PCRX | S 10b5-1 | 5,000 | $62.00 | $310,000 | 34,785 Direct | -12.57% | Disposed | -60.1% (price as of 2026-10-06) |
| June 9, 2020 | PCRX | A | 35,000 | · | · | 35,000 Direct | · | Acquired | (price as of 2026-10-06) |
| June 9, 2020 | PCRX | A | 14,000 | · | · | 39,237 Direct | +55.47% | Acquired | (price as of 2026-10-06) |
| March 11, 2020 | PCRX | P | 2,500 | $36.50 | $91,250 | 25,237 Direct | +11.00% | Acquired | -32.2% (price as of 2026-10-06) |
| June 5, 2019 | PCRX | A | 33,800 | · | · | 33,800 Direct | · | Acquired | (price as of 2026-10-06) |
| June 5, 2019 | PCRX | A | 5,600 | · | · | 22,139 Direct | +33.86% | Acquired | (price as of 2026-10-06) |
| June 4, 2019 | PCRX | S | 722 | $42.91 | $30,981 | 16,539 Direct | -4.18% | Disposed | -42.3% (price as of 2026-10-06) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 14, 2023 | PCRX | Stock Option (Right to Buy) | Common Stock | $38.74 | June 14, 2033 | 27,500 | Acquired |
| June 8, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $59.39 | June 8, 2032 | 24,800 | Acquired |
| June 6, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $34.38 | May 2, 2028 | 6,250 | Disposed |
| Nov. 4, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $48.15 | May 2, 2027 | 10,000 | Disposed |
| Aug. 3, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $60.79 | July 20, 2031 | 10,000 | Acquired |
| June 9, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $60.96 | June 9, 2031 | 17,500 | Acquired |
| March 31, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $34.38 | May 2, 2028 | 13,750 | Disposed |
| June 9, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock | $47.65 | June 9, 2030 | 35,000 | Acquired |
| June 5, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock | $43.54 | June 5, 2029 | 33,800 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 7 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Sept. 7, 2018 | PCRX | Common Stock | 16,500 | Direct |
| Sept. 7, 2018 | PCRX | Stock Option (Right to Buy) | 37,500 | Direct |
| Sept. 7, 2018 | PCRX | Stock Option (Right to Buy) | 20,000 | Direct |
| Sept. 7, 2018 | PCRX | Stock Option (Right to Buy) | 10,000 | Direct |
| Sept. 7, 2018 | PCRX | Stock Option (Right to Buy) | 6,000 | Direct |
| Sept. 7, 2018 | PCRX | Stock Option (Right to Buy) | 25,000 | Direct |
| Sept. 7, 2018 | PCRX | Stock Option (Right to Buy) | 10,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2019 | $408,654 | $225,000 | $243,824 | $720,919 | · | · | $13,403 | $1,611,800 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.